

15 May 1977

Vol. 19 No. 5

INTERNATIONAL

*Journal
of Cancer*

**JOURNAL INTERNATIONAL
DU CANCER**

BIOLOGY LIBRARY



Publication of the International Union Against Cancer

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

INTERNATIONAL *Journal* of Cancer

JOURNAL INTERNATIONAL DU CANCER

Editor-in-Chief: E. A. Saxén
Assistant Editor: E. Saksela
Managing Editor: F. Luder

Editorial Office: International Journal of Cancer,
Third Dept. of Pathology, University of Helsinki,
Helsinki 29, Finland

EDITORIAL BOARD

Comité de rédaction

S. A. AARONSON, Bethesda, Md. (USA)
G. I. ABELEV, Moscow (USSR)
R. W. BALDWIN, Nottingham (England)
S. BARON, Bethesda, Md. (USA)
GEORGES BARSKI, Villejuif (France)
M. M. BURGER, Basel (Switzerland)
VITTORIO DEFENDI, New York, N.Y. (USA)
LEILA DIAMOND, Philadelphia, Pa. (USA)
Sir RICHARD DOLL, Oxford (England)
S. J. ECKHARDT, Budapest (Hungary)
H. HANAFUSA, New York, N.Y. (USA)
JENNIFER J. HARVEY, Harrow (England)
H. ZUR HAUSEN, Erlangen (Germany)
CH. HEIDELBERGER, Madison, Wisconsin, (USA)
SAUL KIT, Houston, Texas (USA)
H. G. KWA, Amsterdam (Netherlands)
ALBERT LEVAN, Lund (Sweden)
R. MENEGHINI, Sao Paulo (Brazil)
DONALD METCALF, Melbourne (Australia)
ERNA MÖLLER, Stockholm (Sweden)
C. S. MUIR, Lyons (France)

N. P. NAPALCOV, Leningrad (USSR)
ESKO NIKKILÄ, Helsinki (Finland)
K. NISHIOKA, Tokyo (Japan)
T. ONOÉ, Sapporo (Japan)
J. PONTÉN, Uppsala (Sweden)
R. T. PREHN, Philadelphia, Pa. (USA)
V. RAMALINGASWAMI, New Delhi (India)
J. J. ROBERTS, Chalfont St. Giles (England)
E. RUOSLAHTI, Duarte, Calif. (USA)
LEO SACHS, Rehovot (Israel)
D. SCHMÄHL, Heidelberg (Germany)
K. SHANMUGARATNAM, Singapore
H. O. SJÖGREN, Lund (Sweden)
J. SVOBODA, Prague (Czechoslovakia)
V. THURZO, Bratislava (Czechoslovakia)
L. TOMATIS, Lyons (France)
J. M. VASILIEV, Moscow (USSR)
U. VERONESI, Milan (Italy)
D. M. WHITELAW, Vancouver (Canada)
A. O. WILLIAMS, Ibadan (Nigeria)



COUNCIL — CONSEIL

F. de AMESTI (Chile/Chili)	D. METCALF (Australia/Australie)
N. N. BLOKHIN (USSR/URSS)	A. MOJTABAI (Iran)
M. COPELAND (USA/EU)	G. P. MURPHY (USA/EU)
P. DENOIX, Président (France)	K. OOTA (Japan/Japon)
R. DOLL (UK/RU)	I. PADOVAN (Yugoslavia/Yougoslavie)
S. ECKHARDT (Hungary/Hongrie)	E. A. SAXÉN (Finland/Finlande)
I. ELSEBAI (Egypt/Egypte)	C. G. SCHMIDT (Germany/Allemagne)
B. E. GUSTAFSSON (Sweden/Suède)	K. SHANMUGARATNAM (Singapore/Singapour)
E. HECKER (Germany/Allemagne)	M. SUGIMURA (Japan/Japon)
A. C. JUNQUEIRA (Brazil/Brésil)	R. M. TAYLOR (Canada)
D. J. JUSSAWALLA (India/Inde)	N. TRAININ (Israel/Israël)
H. KASDORF (Uruguay)	N. N. TRAPEZNIKOV (USSR/URSS)
L. G. LAJTHA (UK/RU)	U. VERONESI (Italy/Italie)
R. LEE CLARK (USA/EU)	F. J. WILCOX (USA/EU)
P. LOUSTALOT (Switzerland/Suisse)	A. WILLIG (USA/EU)
F. F. McEACHREN (Canada)	

INTERNATIONAL UNION AGAINST CANCER

The International Union Against Cancer is a non-governmental, voluntary organization devoted solely to promoting throughout the world the campaign against cancer in its research, therapeutic and preventive aspects. Over the years, the UICC has developed into a world-wide association with member-organizations in over 79 countries. It strives to achieve its aim by facilitating the exchange of information between national cancer organizations, holding international cancer congresses, conferences and symposia, standardizing nomenclatures and classifications, and by stimulating national efforts against cancer.

The UICC publishes the *International Journal of Cancer*, Monographs, Manuals, Technical Reports, and the *UICC Bulletin*. The International Union Against Cancer has received financial assistance for the publication of the *International Journal of Cancer* from the *U. S. National Institutes of Health*, the *Calouste Gulbenkian Foundation*, the *Swedish Cancer Society*, the *Canadian Cancer Society*, the *National Cancer Institute of Canada*, and the *Cancer Society of Finland*.

UNION INTERNATIONALE CONTRE LE CANCER

L'Union Internationale Contre le Cancer, au sein de laquelle sont groupées des sociétés membres de plus de 79 pays, est une organisation non gouvernementale sans but lucratif, qui se consacre exclusivement à encourager dans le monde entier la lutte contre le cancer: thérapeutique, prophylaxie et recherche. A cette fin, elle facilite les échanges d'informations entre sociétés nationales, organise des congrès, conférences et symposiums internationaux, unifie les nomenclatures et les classifications et stimule l'action menée contre le cancer sur le plan national.

L'UICC publie le *Journal International du Cancer*, des Monographies, Manuels, Rapports techniques, et le *Bulletin de l'UICC*. L'Union Internationale Contre le Cancer a reçu pour la publication du *Journal International du Cancer* l'aide financière des institutions suivantes: *the National Institutes of Health (USA)*, *Fondation Calouste Gulbenkian*, *the Swedish Cancer Society*, *Société Canadienne du Cancer*, *Institut National du Cancer du Canada*, et *the Cancer Society of Finland*.

CHARACTERIZATION OF EBV-GENOME NEGATIVE "NULL" AND "T" CELL LINES DERIVED FROM CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LEUKEMIC TRANSFORMED NON-HODGKIN LYMPHOMA

Ulrich SCHNEIDER, Hans-Ulrich SCHWENK, and Georg BORNKAMM

Kinderklinik der Universität Erlangen-Nürnberg, and Institut für Klinische Virologie der Universität Erlangen-Nürnberg, D-8520 Erlangen, Loschgestr., Federal Republic of Germany

Sixty-two explants from peripheral blood, bone marrow and cerebral fluid of children with acute lymphoblastic leukemia (ALL) and leukemic transformed non-Hodgkin lymphoma (NHL) were cultivated for at least 8 weeks. Although lymphatic cells persisted up to 16 weeks in tissue culture, no proliferation was observed in 54 cultures. From the remaining cultures, eight permanently growing cell lines were obtained. Five of these were EBNA (Epstein-Barr virus-specific nuclear antigen)-positive. Three, however, were EBNA-negative and lacked Epstein-Barr virus genomes. Two cell lines (KM-3 and SH-2) expressed neither B nor T cell characteristics. One line (JM) expressed T cell characteristics and complement receptors. The growing lymphatic cells represented leukemic cells, since the pattern of cytochemical staining and that of membrane receptors of lymphoblasts from the same donor prior to cultivation were identical. All leukemic cell lines were derived from patients in relapse. In contrast, no proliferation of leukemic cells occurred in explants from patients revealing the first manifestation of the disease. These results suggest enhanced growth potential of lymphoblasts resisting antileukemic therapy.

Acute lymphoblastic leukemia (ALL) contributes up to 35% of all childhood malignancies. Although the prognosis of ALL improved after introduction of more efficient radio- and chemotherapy (Pinkel *et al.*, 1972), about 50% of the patients relapsed within 5 years after first remission (Aur *et al.*, 1974). Similarly, a great number of children suffering from non-Hodgkin lymphoma (NHL) terminate in leukemic generalization. Therefore, early recognition of patients with high risk of relapse would be important for the prognosis and possibly also for an initial intensification of the therapy in this group. A considerable number of these patients express T cell surface markers (Borella *et al.*, 1973), although relapses occur in T-marker negative ALL as well. In the latter group different parameters (initial leukocyte count, age of the patient) may allow some prediction of prognosis. Nevertheless a better characterization of the lymphoblasts is urgently needed.

Leukemic cell lines represent an excellent tool in the search for tumor-specific characteristics. The almost unlimited quantity, the lack of contami-

nation by normal leukocytes and their convenient availability are helpful in many experimental designs. As a prerequisite, however, the lack of Epstein-Barr virus (EBV) genomes and the identity of properties of cultured cells and primary tumor cells have to be ensured. Up to now these criteria have been fulfilled in only a few cell lines established from children with T-cell receptor-positive ALL or NHL (Foley *et al.*, 1965; Adams *et al.*, 1968; Minowada *et al.*, 1972, 1977). The permanent growth of T and B cell receptor-negative cells in childhood ALL has not been reported thus far. In this communication we describe the establishment of two leukemic "null" and of a T receptor-positive line.

MATERIAL AND METHODS

Origin and maintenance of the cell lines used as controls

The cell lines Raji (Pulvertaft, 1964), U-698 M (Nilsson and Sundström, 1974), Ramos (Klein *et al.*, 1975) and MOLT-4 (Minowada *et al.*, 1972) were kindly provided by Dr. H. zur Hausen, Erlangen. The cell cultures were incubated at 37°C and subcultivated once or twice weekly with medium RPMI 1640, supplemented with 10% inactivated fetal calf serum, 100 IU/ml penicillin and 100 µg/ml streptomycin.

Establishment of the cell lines

Blood and bone-marrow samples were centrifuged on a Ficoll-Hypaque gradient (Böyum, 1968) after 1:2 dilution in medium RPMI 1640, supplemented with fetal calf serum and antibiotics as described above. Ten samples derived from five patients were injected into Spongostan foam (Ferrosan, Malmö, Sweden) and layered on a grid of stainless steel according to the method of Nilsson (1971). The cultures were incubated at 37°C in a 5% CO₂ atmosphere and observed for at least 8 weeks. One-half to one-third of the medium was changed twice weekly.

Received: December 3, 1976.

CHARACTERIZATION OF EBV-GENOME NEGATIVE "NULL" AND "T" CELL LINES DERIVED FROM CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LEUKEMIC TRANSFORMED NON-HODGKIN LYMPHOMA

Ulrich SCHNEIDER, Hans-Ulrich SCHWENK, and Georg BORNKAMM

Kinderklinik der Universität Erlangen-Nürnberg, and Institut für Klinische Virologie der Universität Erlangen-Nürnberg, D-8520 Erlangen, Loschgestr., Federal Republic of Germany

Sixty-two explants from peripheral blood, bone marrow and cerebral fluid of children with acute lymphoblastic leukemia (ALL) and leukemic transformed non-Hodgkin lymphoma (NHL) were cultivated for at least 8 weeks. Although lymphatic cells persisted up to 16 weeks in tissue culture, no proliferation was observed in 54 cultures. From the remaining cultures, eight permanently growing cell lines were obtained. Five of these were EBNA (Epstein-Barr virus-specific nuclear antigen)-positive. Three, however, were EBNA-negative and lacked Epstein-Barr virus genomes. Two cell lines (KM-3 and SH-2) expressed neither B nor T cell characteristics. One line (JM) expressed T cell characteristics and complement receptors. The growing lymphatic cells represented leukemic cells, since the pattern of cytochemical staining and that of membrane receptors of lymphoblasts from the same donor prior to cultivation were identical. All leukemic cell lines were derived from patients in relapse. In contrast, no proliferation of leukemic cells occurred in explants from patients revealing the first manifestation of the disease. These results suggest enhanced growth potential of lymphoblasts resisting antileukemic therapy.

Acute lymphoblastic leukemia (ALL) contributes up to 35% of all childhood malignancies. Although the prognosis of ALL improved after introduction of more efficient radio- and chemotherapy (Pinkel *et al.*, 1972), about 50% of the patients relapsed within 5 years after first remission (Aur *et al.*, 1974). Similarly, a great number of children suffering from non-Hodgkin lymphoma (NHL) terminate in leukemic generalization. Therefore, early recognition of patients with high risk of relapse would be important for the prognosis and possibly also for an initial intensification of the therapy in this group. A considerable number of these patients express T cell surface markers (Borella *et al.*, 1973), although relapses occur in T-marker negative ALL as well. In the latter group different parameters (initial leukocyte count, age of the patient) may allow some prediction of prognosis. Nevertheless a better characterization of the lymphoblasts is urgently needed.

Leukemic cell lines represent an excellent tool in the search for tumor-specific characteristics. The

limited quantity, the lack of contamination by normal leukocytes and their convenient availability are helpful in many experimental designs. As a prerequisite, however, the lack of Epstein-Barr virus (EBV) genomes and the identity of properties of cultured cells and primary tumor cells have to be ensured. Up to now these criteria have been fulfilled in only a few cell lines established from children with T-cell receptor-positive ALL or NHL (Foley *et al.*, 1965; Adams *et al.*, 1968; Minowada *et al.*, 1972, 1977). The permanent growth of T and B cell receptor-negative cells in childhood ALL has not been reported thus far. In this communication we describe the establishment of two leukemic "null" and of a T receptor-positive line.

MATERIAL AND METHODS

Origin and maintenance of the cell lines used as controls

The cell lines Raji (Pulvertaft, 1964), U-698 M (Nilsson and Sundström, 1974), Ramos (Klein *et al.*, 1975) and MOLT-4 (Minowada *et al.*, 1972) were kindly provided by Dr. H. zur Hausen, Erlangen. The cell cultures were incubated at 37°C and subcultivated once or twice weekly with medium RPMI 1640, supplemented with 10% inactivated fetal calf serum, 100 IU/ml penicillin and 100 µg/ml streptomycin.

Establishment of the cell lines

Blood and bone-marrow samples were centrifuged on a Ficoll-Hypaque gradient (Böyum, 1968) after 1:2 dilution in medium RPMI 1640, supplemented with fetal calf serum and antibiotics as described above. Ten samples derived from five patients were injected into Spongostan foam (Ferrosan, Malmö, Sweden) and layered on a grid of stainless steel according to the method of Nilsson (1971). The cultures were incubated at 37°C in a 5% CO₂ atmosphere and observed for at least 8 weeks. One-half to one-third of the medium was changed twice weekly.

Received: December 3, 1976.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.